Clinical and demographic patients data according to visit and genotypes
| All patients (n = 91) | FCGR2A | FCGR3A | |||||
| HH n = 20 (22.0%) | HR n = 48 (52.7%) | RR n = 23 (25.3%) | VV n = 16 (19.5%) | VF n = 35 (42.7%) | FF n = 31 (37.8%) | ||
| Age, years | 56.0 (12.9) | 52.9 (11.3) | 59.0 (12.3) | 52.4 (14.1) | 56.1 (12.5) | 53.9 (11.6) | 57.5 (14.7) |
| Female (%) | 81 (89.0%) | 18 (90.0%) | 44 (91.7%) | 19 (82.6%) | 14 (87.5%) | 30 (85.7%) | 28 (90.3%) |
| RF positive | 69 (76.7%) | 16 (80.0%) | 36 (75.0%) | 17 (77.3%) | 14 (87.5%) | 26 (74.3%) | 26 (84.0%) |
| ACPA positive | 57 (62.6%) | 8 (40.0%) | 36 (75.0%) | 15 (65.5%) | 7 (43.7%) | 25 (71.4%) | 21 (67.7%) |
| Disease duration, years | 10.6 (6.4) | 11.0 (9.4) | 11.2 (7.9) | 9.0 (6.5) | 9.9 (3.9) | 10.2 (9.4) | 10.5 (6.4) |
| DAS28 3v-CRP: | |||||||
| Baseline | 4.5 (1.0) | 4.1 (0.9) | 4.5 (1.1) | 4.6 (1.0) | 4.5 (1.0) | 4.4 (1.1) | 4.5 (1.2) |
| Week 6 | 3.3 (1.1) | 3.3 (1.0) | 3.3 (1.2) | 3.3 (1.2) | 3.6 (1.2) | 3.6 (1.0) | 3.0 (1.0) |
| Week 30 | 3.4 (1.2) | 3.5 (1.1) | 3.5 (1.3) | 3.1 (1.1) | 3.5 (1.3) | 3.4 (1.0) | 5.1 (2.5) |
| CRP: | |||||||
| Baseline | 3.0 (2.8) | 3.2 (3.1) | 3.0 (2.6) | 3.1 (3.1) | 3.9 (3.2) | 2.3 (2.6) | 3.5 (2.9) |
| Week 6 | 1.4 (2.6) | 1.7 (3.9) | 1.6 (2.4) | 0.8 (1.3) | 2.0 (3.3) | 1.6 (3.3) | 1.1 (1.3) |
| Week 30 | 1.9 (2.6) | 2.2 (3.4) | 2.1 (2.7) | 1.4 (1.9) | 1.9 (2.3) | 1.6 (2.8) | 1.9 (1.6) |
| ESR: | |||||||
| Baseline | 44.9 (24.7) | 44.7 (29.1) | 48.1 (24.4) | 38.6 (20.6) | 43.6 (24.4) | 42.8 (25.6) | 49.1 (25.9) |
| Week 6 | 34.1 (24.7) | 30.8 (26.1) | 38.7 (26.1) | 27.4 (18.6) | 31.4 (26.4) | 33.9 (25.1) | 38.9 (24.0) |
| Week 30 | 37.0 (26.1) | 38.2 (30.9) | 39.9 (25.5) | 29.9 (22.6) | 33.6 (22.8) | 34.8 (29.3) | 42.5 (22.9) |
| Swollen joint count: | |||||||
| Baseline | 9.4 (6.4) | 8.7 (5.3) | 8.8 (6.6) | 11.2 (6.9) | 9.8 (6.2) | 9.7 (6.1) | 9.6 (7.1) |
| Week 6 | 3.9 (4.2) | 3.1 (2.4) | 4.1 (4.8) | 4.4 (4.2) | 5.0 (3.8) | 4.3 (4.9) | 3.4 (3.9) |
| Week 30 | 3.9 (4.4) | 5.6 (5.3) | 4.0 (4.5) | 1.9 (2.4) | 4.6 (4.0) | 4.5 (5.4) | 3.1 (3.4) |
| Tender joint count: | |||||||
| Baseline | 12.1 (8.6) | 8.3 (7.2) | 13.5 (8.9) | 12.7 (8.3) | 10.7 (7.5) | 13.8 (9.0) | 11.9 (9.1) |
| Week 6 | 7.2 (7.0) | 6.9 (6.4) | 7.4 (7.3) | 7.2 (7.0) | 7.4 (6.3) | 9.9 (8.1) | 4.7 (5.3) |
| Week 30 | 7.7 (8.0) | 7.0 (8.0) | 8.3 (8.3) | 7.0 (7.4) | 6.7 (6.8) | 8.9 (8.7) | 7.4 (8.3) |
| Modified HAQ: | |||||||
| Baseline | 1.3 (0.6) | 1.3 (0.7) | 1.4 (0.6) | 1.2 (0.6) | 1.3 (0.7) | 1.4 (0.7) | 1.4 (0.6) |
| Week 6 | 0.9 (0.6) | 1.1 (0.7) | 0.9 (0.6) | 0.9 (0.6) | 0.9 (0.5) | 1.0 (0.7) | 0.9 (0.6) |
| Week 30 | 1.0 (1.0) | 1.1 (0.6) | 1.1 (1.2) | 0.7 (0.5) | 1.3 (1.9) | 1.0 (0.7) | 1.0 (0.5) |
| Physician Global Assessment: | |||||||
| Baseline | 63.7 (15.3) | 61.9 (17.5) | 64.2 (13.3) | 64.1 (17.6) | 64.0 (15.3) | 65.7 (15.0) | 64.5 (14.4) |
| Week 6 | 38.7 (17.5) | 46.0 (9.8) | 39.3 (20.1) | 31.6 (14.3) | 43.9 (12.6) | 40.2 (18.5) | 36.9 (18.1) |
| Week 30 | 40.7 (17.3) | 44.3 (11.0) | 42.9 (18.7) | 33.2 (16.6) | 40.9 (15.7) | 38.6 (18.6) | 44.8 (14.8) |
| Patient Global Assessment: | |||||||
| Baseline | 68.3 (18.6) | 68.3 (18.8) | 68.3 (17.8) | 68.4 (20.9) | 66.1 (21.2) | 69.3 (18.4) | 68.9 (18.4) |
| Week 6 | 44.2 (18.8) | 51.6 (18.6) | 44.4 (19.0) | 37.4 (16.9) | 47.9 (12.8) | 45.0 (21.3) | 42.6 (19.5) |
| Week 30 | 48.4 (18.1) | 52.3 (17.5) | 46.6 (16.7) | 48.8 (21.3) | 47.4 (16.6) | 44.7 (15.5) | 54.2 (21.4) |
All values are mean (SD) unless otherwise stated.
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor.